Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Cash from Financing Activities (2016 - 2025)

Nutex Health's Cash from Financing Activities history spans 13 years, with the latest figure at -$45.8 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 1433.52% year-over-year to -$45.8 million; the TTM value through Dec 2025 reached -$97.9 million, down 9077.91%, while the annual FY2025 figure was -$97.9 million, 9077.91% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$45.8 million at Nutex Health, down from -$29.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.7 million in Q1 2024 and bottomed at -$68.9 million in Q2 2021.
  • The 5-year median for Cash from Financing Activities is -$5.5 million (2023), against an average of -$13.7 million.
  • The largest YoY upside for Cash from Financing Activities was 1984.0% in 2021 against a maximum downside of 23781.37% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at -$32.8 million in 2021, then surged by 54.99% to -$14.8 million in 2022, then surged by 73.47% to -$3.9 million in 2023, then increased by 23.72% to -$3.0 million in 2024, then tumbled by 1433.52% to -$45.8 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Cash from Financing Activities are -$45.8 million (Q4 2025), -$29.9 million (Q3 2025), and -$15.4 million (Q2 2025).